It’s only fair to share… Canlitinib Cas 2222730-78-9 Molecular Weight 619.61 Formula C33H31F2N3O7 6-[4-[2-fluoro-4-[[1-[(4-fluorophenyl)carbamoyl]cyclopropanecarbonyl]amino]phenoxy]-6-methoxyquinolin-7-yl]oxyhexanoic acid CANLITINIB is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication. Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for cancer study. Kanitinib is a tyrosine kinase inhibitor targeting the oncoprotein …